The CoNNCT Initiative: Accelerating Novel Combinations For Cancer
Executive Summary
Combination therapies are the cornerstone of oncology, but the development model has been slow to shift to early testing of combinations of investigational drugs. The CoNNCT initiative aims to accelerate clinical testing of novel-novel combinations, and in doing so provide benefits for biopharma, clinicians and the cancer patients they serve.
You may also be interested in...
Key Trends In Immuno-Oncology Dealmaking
Big Pharma and Mid Pharma companies have signed over 200 immuno-oncology deals in the last five years, creating the most lucrative class in dealmaking, according to a recent Datamonitor Healthcare report. Bristol-Myers Squibb and Merck & Co. have led the charge, and the PD-L1/PD-1 target still dominates.
Revisiting Cell Screening To Find New Cancer Drug Combos
Evidence is slowly building of the potential of high-throughput screening of individual patient tumors to test their sensitivity and response to hundreds of combinations of cancer drugs, first in leukemia and hopefully for treating other cancers.